https://pubmed.ncbi.nlm.nih.gov/34227094/

5018

Reardon S. FDA approves Alzheimer’s drug lecanemab amid safety concerns. Nature. 2023;613(7943):227–8. https://pubmed.ncbi.nlm.nih.gov/36627422/

5019

Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer’s disease. BMJ. 2022;379. https://pubmed.ncbi.nlm.nih.gov/36535691/

5020

Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808. https://pubmed.ncbi.nlm.nih.gov/22506132/

5021

Price JL. What does it take to stay healthy past 100? Neurobiol Aging. 2008;29(8):1140–2. https://pubmed.ncbi.nlm.nih.gov/18524418/

5022

Barber RC. The genetics of Alzheimer’s disease. Scientifica (Cairo). 2012;2012:246210. https://pubmed.ncbi.nlm.nih.gov/24278680/

5023

Castello MA, Soriano S. On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev. 2014;13:10–2. https://pubmed.ncbi.nlm.nih.gov/24252390/

5024

Ayton S, Bush AI. ß-amyloid: the known unknowns. Ageing Res Rev. 2021;65:101212. https://pubmed.ncbi.nlm.nih.gov/33188924/

5025

SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL. Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol. 2011;70(10):832–40. https://pubmed.ncbi.nlm.nih.gov/21937909/

5026

Ayton S, Bush AI. ß-amyloid: the known unknowns. Ageing Res Rev. 2021;65:101212. https://pubmed.ncbi.nlm.nih.gov/33188924/

5027

Alzheimer A, Förstl H, Levy R. On certain peculiar diseases of old age. Hist Psychiatry. 1991;2(5):71–3. https://pubmed.ncbi.nlm.nih.gov/11622845/

5028

Piller C. Blots on a field? Science. 2022;377(6604):358–63. https://pubmed.ncbi.nlm.nih.gov/35862524/

5029

Ayton S, Bush AI. ß-amyloid: the known unknowns. Ageing Res Rev. 2021;65:101212. https://pubmed.ncbi.nlm.nih.gov/33188924/

5030

Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. 2012;2012:369808. https://pubmed.ncbi.nlm.nih.gov/22506132/

5031

Amtul Z. Why therapies for Alzheimer’s disease do not work: do we have consensus over the path to follow? Ageing Res Rev. 2016;25:70–84. https://pubmed.ncbi.nlm.nih.gov/26375861/

5032

Ayton S, Bush AI. ß-amyloid: the known unknowns. Ageing Res Rev. 2021;65:101212. https://pubmed.ncbi.nlm.nih.gov/33188924/

5033

Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA. Copernicus revisited: amyloid beta in Alzheimer’s disease. Neurobiol Aging. 2001;22(1):131–46. https://pubmed.ncbi.nlm.nih.gov/11164287/

5034

Ayton S, Bush AI. ß-amyloid: the known unknowns. Ageing Res Rev. 2021;65:101212. https://pubmed.ncbi.nlm.nih.gov/33188924/

5035

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7. https://pubmed.ncbi.nlm.nih.gov/9330961/

5036

Grodstein F. How early can cognitive decline be detected? BMJ. 2011;344:d7652. https://pubmed.ncbi.nlm.nih.gov/22223829/

5037

Torres-Acosta N, O’Keefe JH, O’Keefe EL, Isaacson R, Small G. Therapeutic potential of TNF-a inhibition for Alzheimer’s disease prevention. J Alzheimers Dis. 2020;78(2):619–26. https://pubmed.ncbi.nlm.nih.gov/33016914/

5038

Viña J, Sanz-Ros J. Alzheimer’s disease: only prevention makes sense. Eur J Clin Invest. 2018;48(10):e13005. https://pubmed.ncbi.nlm.nih.gov/30028503/

5039

de la Torre JC. Alzheimer’s disease is incurable but preventable. J Alzheimers Dis. 2010;20(3):861–70. https://pubmed.ncbi.nlm.nih.gov/20182017/

5040

Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28. https://pubmed.ncbi.nlm.nih.gov/21775213/

5041

Singh-Manoux A, Kivimaki M, Glymour MM, et al. Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ. 2012;344:d7622. https://pubmed.ncbi.nlm.nih.gov/22223828/

5042

Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44. https://pubmed.ncbi.nlm.nih.gov/21388893/

5043

Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde.” Clin Anat. 1995;8(6):429–31. https://pubmed.ncbi.nlm.nih.gov/8713166/

5044

Sharma M. Preventing Alzheimer’s disease: some light in the darkness. J Am Coll Cardiol. 2019;74(15):1924–5. https://pubmed.ncbi.nlm.nih.gov/31601372/

5045

Grande G, Qiu C, Fratiglioni L. Prevention of dementia in an ageing world: evidence and biological rationale. Ageing Res Rev. 2020;64:101045. https://pubmed.ncbi.nlm.nih.gov/32171784/

5046

Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44. https://pubmed.ncbi.nlm.nih.gov/21388893/

5047

Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749–56. https://pubmed.ncbi.nlm.nih.gov/23204143/

5048

Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology. 2005;64(3):494–500. https://pubmed.ncbi.nlm.nih.gov/15699381/

5049

Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44. https://pubmed.ncbi.nlm.nih.gov/21388893/

5050

de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Ann N Y Acad Sci. 2002;977:196–215. https://pubmed.ncbi.nlm.nih.gov/12480752/

5051

Cahill S, Pierce M, Werner P, Darley A, Bobersky A. A systematic review of the public’s knowledge and understanding of Alzheimer’s disease and dementia. Alzheimer Dis Assoc Disord. 2015;29(3):255–75. https://pubmed.ncbi.nlm.nih.gov/26207322/

5052

Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer’s disease. Mol Nutr Food Res. 2011;55 Suppl 2:S161–72. https://pubmed.ncbi.nlm.nih.gov/21954186/

5053

Mizuno T, Nakata M, Naiki H, et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem. 1999;274(21):15110–4. https://pubmed.ncbi.nlm.nih.gov/10329717/

5054

Harris JR, Milton NGN. Cholesterol in Alzheimer’s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75. https://pubmed.ncbi.nlm.nih.gov/20213540/

5055

US Food and Drug Administration. Important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Published July 7, 2012. Accessed June 30, 2022.; https://www.fda.gov/Drugs/DrugSafety/ucm293101.htm

5056

Rojas-Fernandez